Lightnews — Scholar-powered news

exai bio @exai.bio · Jul 23

We’re excited to welcome Michael Nall as CEO and Board Director and new Board Directors - Steve Kafka, PhD, of S32, Dusan Perovic of Two Sigma Ventures and Emir Sandhu, MD, of Blue Venture Fund. Their leadership will be invaluable as we advance our RNA & AI liquid biopsy platform.

1

exai bio @exai.bio · Jun 6

Reflecting on a productive week of meetings at ASCO! Thank you to all those who visited our Innovation Hub booth to learn more about our technology. #ASCO25 #LiquidBiopsy #AI #RNA

1

exai bio @exai.bio · Jun 2

Congratulations to our Board Director Karen Knudsen MBA PhD for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). We are so grateful for your leadership, passion and the profound impact you have on the cancer community. #ASCO25 #Leadership

3

exai bio @exai.bio · May 15

💥New Publication Alert in Clinical Cancer Research💥
We are thrilled to announce our latest publication on our novel RNA and generative AI liquid biopsy platform for early colorectal cancer detection. #EarlyDetection #LiquidBiopsy #RNA
Read the full publication here: aacrjournals.org/clincancerre...

Detection of Early-Stage Colorectal Cancer Using Cell-Free oncRNA Biomarkers and Artificial Intelligence

Abstract. Purpose: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide, and early detection significantly improves treatment outcomes, but existing blood-based tests...

aacrjournals.org

3 6

exai bio @exai.bio · Apr 30

www.exai.bio/publications...

Detection of early stage colorectal cancer using cell-free oncRNA biomarkers and AI

We demonstrate high sensitivity and specificity were achieved, including 80% sensitivity for stage I CRC with a novel small RNA biomarker, oncRNA, combined with generative AI detects early-stage CRC u...

www.exai.bio

2

exai bio @exai.bio · Apr 30

Exai Bio presented new data demonstrating the power of its RNA and AI based liquid biopsy platform to detect colorectal cancer. Stage I sensitivity in an independent cohort was 80%, exceeding other blood based approaches. Thanks to Amir Momen-Roknabadi for representing Exai Bio at #AACR25!

Amir Momen-Roknabadi representing Exai Bio at AACR 2025

1 1 6

exai bio @exai.bio · Feb 19

DYK almost half of all women have dense breast tissue which means they are at higher risk of developing breast cancer? Exai is joining My Density Matters to spread awareness that today is Find Out My Breast Density Day. Talk to your doctor if you have questions. #BreastDensity #EarlyDetection

1 2

exai bio @exai.bio · Feb 4

Together we unite to fight cancer and inspire hope.
#WorldCancerDay #UnitedByUnique #EarlyDetection #BreastCancer

2

exai bio @exai.bio · Jan 29

Congratulations to our Board Director Karen Knudsen for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). Your tremendous leadership and dedication continue to make a profound impact on cancer care. #ASCO25
connection.asco.org/do/asco-cong...

ASCO Congratulates 2025 Special Awards Recipients

ASCO and Conquer Cancer will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest

connection.asco.org

2

exai bio @exai.bio · Jan 28

Our own Mehran Karimzadeh wrote a blog post about our recent Nature Communications publication demonstrating superior cancer detection performance by Exai’s AI platform compared to traditional machine learning methods. #AI #EarlyDetection #LungCancer
communities.springernature.com/posts/behind...

Behind the paper: Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer

Our recent study in Nature Communications highlights the success of a custom generative AI framework in detecting non-small cell lung cancer and its subtypes from serum-derived orphan non-coding RNAs.

communities.springernature.com

3

exai bio @exai.bio · Jan 20

Today, we honor the legacy of Dr. Martin Luther King Jr., whose words continue to inspire: “The time is always right to do what is right.” At Exai, we are committed to doing what is right—advancing cancer detection and ensuring a future where everyone has access to early detection and better health.

1

exai bio @exai.bio · Dec 5

We are honored to welcome Karen E. Knudsen, MBA, PhD, to our board of directors. As an internationally recognized oncology leader and immediate past CEO of the American Cancer Society and its advocacy affiliate ACS CAN, Karen is deeply committed to ending cancer as we know it.

2

exai bio @exai.bio · Nov 21

💥New Publication Alert in Nature Communications 💥
Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods.
Read the full publication here: www.nature.com/articles/s41...

Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer

Nature Communications - A generative AI model, Orion, learns a robust and generalizable pattern of non-small cell lung cancer from cancer-specific circulating non-coding RNAs. Orion enhances the...

www.nature.com

3 6

exai bio @exai.bio · Nov 8

Exai was proud to be part of the inaugural RISE UP For Breast Cancer Meeting hosted by UCSF. #breastcancer #womenshealth #UCSF

1

exai bio @exai.bio · Sep 23

3 years of innovation never looked so sweet! Celebrating Exai’s 3rd anniversary today, one donut (and breakthrough) at a time! #lifeatexai

2

exai bio @exai.bio · Sep 19

Exai was proud to attend #ESMO2024, where we announced new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer

1 3

exai bio @exai.bio · Sep 13

Join us at #ESMO2024 where Exai will present new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer

1 3

exai bio @exai.bio · Jul 24

We’re excited to announce Dave Daly has been appointed as Exai Bio’s CEO. Dave brings more than 30 years of extensive cancer diagnostics and executive leadership experience to lead the next chapter of Exai.
www.exai.bio/news/exai-bi...

1 2

exai bio @exai.bio · Jul 16

1 2

exai bio @exai.bio · Jun 19

Exai celebrates diversity and wishes everyone a very happy Pride Month. #PrideMonth #earlydetection #lifeatexai #MRD

1 2

exai bio @exai.bio · Jun 4

Proud to present our latest RNA- and AI-based #liquidbiopsy research at #ASCO24! #earlydetection #lifeatexai #MRD

1 1 2

exai bio @exai.bio · May 28

Join Exai at #ASCO24 where we will share promising new data. #earlydetection #MRD

1 2

exai bio @exai.bio · Apr 22

Exai co-founder, Hani Goodarzi, in collaboration with Dr. Laura Essserman and Dr. Laura van ‘t Veer from UCSF, posted a preprint, which provides the history of oncRNAs and their power to predict clinical outcomes and monitor disease burden based on the I-SPY 2 Trial. www.biorxiv.org/content/10.1...

1 2

exai bio @exai.bio · Apr 17

1 2

exai bio @exai.bio · Apr 15

The Exai team had a productive week at #AACR24! We were proud to showcase our #liquidbiopsy research in both early cancer detection and MRD. #earlydetection #lifeatexai #MRD

1 3